This guidance applies to all non-exempt human subject research and details events or circumstances that must be promptly reported to the IRB during the conduct of human subject research. “Prompt reporting” is done using the Report Form in eProtocol.

**Events and information which require prompt reporting to the IRB**

1) **Unanticipated Problems Involving Risks to Participants or Others (UPs)**

   Events (internal or external, deaths, life-threatening experiences, injuries, or other) occurring during the research study, which in the opinion of the Monitoring Entity or the PD meet all of the following criteria:

   a) **Unexpected**
      
      in terms of nature, severity, or frequency, given (a) the research procedures described in the protocol-related documents, and (b) the characteristics of the subject population being studied;
      
      **AND**

   b) **Related to participation in the research** or there is a reasonable possibility or likelihood that the incident, experience, or outcome may have been caused by the procedures involved in the research;
      
      **AND**

   c) **Harmful**
      
      the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.

   **NOTE:**

   - A “UP” generally will warrant consideration of substantive changes in the research protocol or informed consent process/document, or other corrective actions, in order to protect the safety, welfare, or rights of subjects or others.
   - **Devices:** If event is associated with a device, report under item 6) UADE.
   - **Any suicide of a participant enrolled at Stanford should be reported promptly, regardless of relatedness.**

2) **New Information** that indicates a change to the risks or potential benefits of the research in terms of severity or frequency or impacts the subject’s willingness to participate (e.g., analysis indicates lower-than-expected response rate; a more severe or frequent side effect; other research finds an arm of study has no therapeutic value; FDA black box warning or withdrawal from market).

3) **Noncompliance, only if:**

   - Possibly serious
     
     Noncompliance that affects the rights or welfare of human subject research participants.
   
   - Possibly continuing
     
     A pattern of noncompliance that continues to occur after a report of noncompliance and a corrective action plan has been reviewed and approved by the IRB, after an investigator has been warned to correct errors or noncompliance, or a circumstance in which an investigator fails to cooperate with investigating or correcting non-compliance.
   
   - Intended to eliminate apparent immediate hazard to research participant

4) **Complaint** unresolved by the research team
5) **Incarceration** when in the opinion of the PD it is in the best interest of the participant to remain on the study.

6) **Unanticipated adverse device effect (UADE)**

   Any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects. 21 CFR 812.3(s)

   More guidance on UADE

7) **Other internal events or information**

   Examples include internal events that are unexpected and related to the research, e.g., suicide or suicide attempt of a participant enrolled at Stanford, Gene Transfer study SAEs, or major deficiencies identified in audits. Report only after consulting with the IRB Panel Manager.

**How to Submit a Report; Timeframes**

- Submit to IRB using eProtocol Report Form (https://eprotocol.stanford.edu/irb)

  - **Timeframe for UP reports depends on Monitoring Entity**

    - If PD is the only monitoring entity
      
      Items 1 - 6 should be reported **directly** to the IRB **within 10 working days** from when the PD learns of the event or new information.

    - If there is a monitoring entity in addition to, or other than, the PD
      
      Report to the IRB using this form **within 10 working days** from receiving assessment from monitoring entity. The PD should report to the IRB when the event has been assessed by the monitoring entity to be a UP.

  - **Timeframe for Reportable Information (items 2 - 6)**

    These should always be reported by the PD **directly** to the IRB **within 10 working days** from when the PD learns of the event or new information.

  - **Unexpected deaths or life-threatening experiences** related to the research (at Stanford, or when STANFORD is the coordinating institution in a multi-site study) must be reported to the IRB **within 5 working days** from PD learning of event.

**Definitions**

1. **Protocol-related documents** refer to the IRB-approved research protocol, informed consent document, investigator brochure, protocol, package insert, or label.

2. **Characteristics of the subject population being studied** refers to the expected natural progression of any underlying disease, disorder, or condition of the subject(s) experiencing the adverse event and the subject’s predisposing risk factor profile for the adverse event.

3. **Related to participation in the research** - In general if event is determined to be caused at least partially by the procedures involved in the research it would be considered **related** to participation in the research; if caused solely by an underlying disease, disorder, or condition of the subject, or other circumstances unrelated to either the research or any underlying disease, disorder, or condition of the subject it would be considered **unrelated** to participation in the research.
4. **Adverse events** need not be “serious” to qualify as “harmful”. However, “serious adverse events” always meet the “Harmful” criterion.

5. **Serious adverse event** only needs to be reported promptly if it is also a UP. An SAE is defined by OHRP as an event that:
   - results in death;
   - is life-threatening (places the subject at immediate risk of death from the event as it occurred);
   - results in inpatient hospitalization or prolongation of existing hospitalization;
   - results in a persistent or significant disability/incapacity;
   - results in a congenital anomaly/birth defect; or
   - based upon appropriate medical judgment, may jeopardize the subject’s health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.

5. **“Not serious“ adverse events might also be UPs:** adverse events that are not serious could also be unanticipated problems if they suggest that the research places subjects or others at a greater risk of physical, psychological, economic, or social harm than was previously known or recognized, e.g. a privacy breach.

6. **FDA-regulated drug studies:** See definitions in FDA regulations at [21 CFR 312.32(a)](http://example.com).

### Resources: Regulations and Guidance

<table>
<thead>
<tr>
<th>OHRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 45 CFR 46.103 (b)(5)</td>
</tr>
<tr>
<td>• Reviewing and Reporting UPs Involving Risks to Subjects or Others and Adverse Events - Guidance</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>• <a href="http://example.com">21 CFR 812.150</a></td>
</tr>
<tr>
<td>Investigational Device – reports</td>
</tr>
<tr>
<td>• <a href="http://example.com">21 CFR 312.32(a)</a></td>
</tr>
<tr>
<td>Investigational New Drug – safety reports</td>
</tr>
<tr>
<td>• <a href="http://example.com">Adverse Event Reporting to IRBs - Improving Human Subject Protection</a> - Guidance</td>
</tr>
</tbody>
</table>

### Resources: Other References

<table>
<thead>
<tr>
<th>Stanford HRPP</th>
</tr>
</thead>
<tbody>
<tr>
<td>• <a href="http://example.com">Ch 3.10</a> Unanticipated Problems Involving Risks to Participants or Others (UPs), and Other Reportable Information</td>
</tr>
<tr>
<td>• <a href="http://example.com">Unanticipated Adverse Device Effect (UADE)</a> [GUI-P14]</td>
</tr>
</tbody>
</table>